Next-Gen Immuno-Oncology: Why Competitive Intelligence Is More Critical Than Ever
I still remember when immuno-oncology first started making waves. The buzz around checkpoint inhibitors was electric—PD-1, PD-L1, CTLA-4—suddenly, we were talking about cancer therapies that could unlock the immune system instead of just targeting the tumor. Fast forward a decade,…